We present here a fatal poisoning case involving verapamil, metoprolol and digoxin. A 39-year-old male was found dead in his room, and a lot of empty packets of prescribed drugs were found near the corpse. The blood concentrations of verapamil, metoprolol and digoxin were 9.2 microg/ml, 3.6 microg/ml and 3.2 ng/ml, respectively. The cause of death was given as cardiac failure, hypotension and bradycardia due to a mixed drug overdose of verapamil, metoprolol and digoxin, based on the results of the autopsy and toxicological examination. We speculate that the toxicity of verapamil is potentiated by drug interaction with metoprolol and digoxin.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/s0379-0738(03)00056-2 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A Case of Atrial Tachycardia Masquerading as Sinus Tachycardia in a Pregnant Female-A Case Report.
Case Rep Cardiol
November 2024
Department of Internal Medicine, BronxCare Health System, Icahn School of Medicine at Mount Sinai, Bronx, New York, USA.
This case report discusses the diagnosis and management of a 25-year-old pregnant patient presenting with persistent tachycardia. The patient, with a past medical history of thyroiditis, polycystic ovarian syndrome, and obesity, was admitted due to palpitations and was diagnosed with atrial tachycardia. Despite medical management with metoprolol, adenosine, digoxin, and flecainide, the tachycardia persisted, necessitating discussion about cardiac ablation.
View Article and Find Full Text PDFTransportability of two heart failure trials to a disease registry using individual patient data.
J Clin Epidemiol
October 2023
School of Health and Wellbeing, University of Glasgow, Glasgow, UK.
Objectives: Randomized controlled trials are the gold-standard for determining therapeutic efficacy, but are often unrepresentative of real-world settings. Statistical transportation methods (hereafter transportation) can partially account for these differences, improving trial applicability without breaking randomization. We transported treatment effects from two heart failure (HF) trials to a HF registry.
View Article and Find Full Text PDF[A pregnant woman with de novo atrial fibrillation].
Ned Tijdschr Geneeskd
June 2023
Tergooi Medisch Centrum, afd. Gynaecologie en Verloskunde, Hilversum/Blaricum.
Background: De novo atrial fibrillation (AF) is rare in pregnancy. The exact pathophysiology of AF is unclear; it might be caused by several cardiovascular and hemodynamic changes that occur in pregnancy, leading to an increased stretch in myocardial cells of the atrial wall.
Case Description: A 26-year-old primigravida with a thus far uncomplicated pregnancy presents with symptoms of heart palpitations, shortness of breath and chest pain.
Influence of Weight and Body Size on the Pharmacokinetics of Heart Failure Pharmacotherapy: A Systematic Review.
Ann Pharmacother
March 2024
Faculty of Pharmacy, Université de Montréal, Montreal, QC, Canada.
Objective: To conduct a review of studies evaluating the influence of body size and weight (WT) on the pharmacokinetics (PK) of drugs recommended for heart failure (HF) treatment.
Data Sources: A systematic search of the MEDLINE (1946 to April 2023) and EMBASE (1974 to April 2023) databases was conducted for articles that focused on the impact of WT or body size on the PK of drugs of interest used in HF patients.
Study Selection And Data Extraction: Articles written in English or French related to the aim of our study were retained for analysis.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!